EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GTN057 , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase

Mikio Okayama, Kota Fujimori, Mariko Sato, Koichi Samata, Koki Kurita, Hiromu Sugiyama, Yutaka Suto, Genji Iwasaki, Taketo Yamada, Fumiyuki Kiuchi, Daiju Ichikawa, Maiko Matsushita und 4 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.5691 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Mikio Okayama und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Despite the development of newly developed drugs, most multiple myeloma (MM) patients with high‐risk cytogenetic abnormalities such as t(4;14) or del17p relapse at anin early stage of their clinical course. We previously reported that a natural product,komaroviquinone (KQN), isolated from the perennial semi‐shrub Dracocephalum komarovi , i.e., komaroviquinone (KQN) and its derivative GTN024 induced the apoptosis of MM cells by producing reactive oxygen species (ROS), but both exhibited significant hematological toxicity. Aim of this study is to clarify anti‐tumor activity, safety and pharmacokinetics of GTN057, an optimization compound of KQN in vivo.

Methods

ICR/SCID xenograft model of KMS11, a t(4;14) translocation‐positive MM cell line, was used for in vivo study. Mice pharmacokinetics of GTN057 and the degradation products were analyzed by LC‐MS/MS.

Results

Herein, our in vitro experiments revealed that GTN057 is much less toxic to normal hematopoietic cells, induced the apoptosis of both MM cell lines andpatient samples, including those with high‐risk cytogenetic changes. A xenograft model of a high‐risk MM cell line demonstrated that GTN057 significantly delayed the tumor growth with no apparent hematological or systemic toxicities in vivo. The pathological examination of GTN057‐treated tumors in vivoshowed revealed apoptosis of MM cells and anti‐angiogenesis. In addition to the production of ROS, GTN057 inhibited the downstream signaling of c‐MET, a receptor tyrosine kinase a receptor forand hepatocyte growth factor (HGF) receptor. Thus, GTN057 is less toxic and is able tomay be a candidate drug for treating MM patients, via multifunctional mechanisms. We have also extensively studied the pharmacologyical analysis of GTN057. The metabolites of GTN057, (e.g.,such as GTN054), may also have anti‐tumorantitumor activity.

Conclusion

Natural products or and their derivatives can could be good sources of antineoplastic drugs even for high‐risk cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansMiceAnimalsReactive Oxygen SpeciesChromatography, LiquidMice, Inbred ICRCell Line, TumorMice, SCIDTandem Mass SpectrometryNeoplasm Recurrence, LocalApoptosisDiterpenesQuinones

Stichwörter der Autor:innen

hepatocyte growth factorkomaroviquinonemultiple myelomanatural producttyrosine kinase inhibition

Substanzen

Reactive Oxygen SpecieskomaroviquinoneDiterpenesQuinones

Autor:innen und Institutionen

  • Division of Clinical Physiology and Therapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.
  • Department of Pathology, Saitama Medical University, Saitama, Japan.
  • Division of Natural Medicines, Keio University Faculty of Pharmacy, Tokyo, Japan.
  • Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

ORCID-Profile: Maki Hirao, Kohei Yamazaki, Yutaka Hattori

Zitieren

APA

Okayama, M., Fujimori, K., Sato, M., Samata, K., Kurita, K., Sugiyama, H., Suto, Y., Iwasaki, G., Yamada, T., Kiuchi, F., Ichikawa, D., Matsushita, M., Hirao, M., Kunieda, H., Yamazaki, K., & Hattori, Y. (2023). GTN057 , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase. Cancer Medicine. https://doi.org/10.1002/cam4.5691

Vancouver

Okayama M, Fujimori K, Sato M, Samata K, Kurita K, Sugiyama H, et al. GTN057 , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase. Cancer Medicine. 2023. doi:10.1002/cam4.5691

BibTeX
@article{Okayama2023,
  author = {Okayama, Mikio and Fujimori, Kota and Sato, Mariko and Samata, Koichi and Kurita, Koki and Sugiyama, Hiromu and Suto, Yutaka and Iwasaki, Genji and Yamada, Taketo and Kiuchi, Fumiyuki and Ichikawa, Daiju and Matsushita, Maiko and Hirao, Maki and Kunieda, Hisako and Yamazaki, Kohei and Hattori, Yutaka},
  title = {GTN057 , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5691}
}
Kostenlos starten →